Idorsia Ltd (IDIA.SW) SIX
4.58
+0.31(+7.25%)
Currency In CHF
- General
- Statistics
- Historical Data
- Profile
- Financials
4.58
+0.31(+7.25%)
Currency In CHF
Address
Hegenheimermattweg 91
Allschwil, 4123
Switzerland
Phone
41 58 844 10 10
Website
Sector
Healthcare
Industry
Biotechnology
Employees
636
First IPO Date
June 16, 2017
| Name | Title | Pay | Year Born |
| Jean-Paul Clozel | Chairman of the Board & Interim CEO | 145,639 | 1955 |
| Srishti Gupta | Chief Executive Officer & Executive Director | 1.22M | 1976 |
| Alberto Gimona | Executive Vice President and Head of Global Clinical Development & Medical Affairs | 821,912 | 1960 |
| André C. Muller | Advisor | 1.19M | 1963 |
| Andrew Jones | Senior Vice President, Head of Corporate Communications & Investor Relations | 0 | 1975 |
| Arno Groenewoud | Executive Vice President & Chief Financial Officer | 0 | 1971 |
| Amer Joseph | Executive VP, Chief Medical Officer & Head of Global Clinical Development | 0 | N/A |
| Martine Clozel | Executive Vice President, Chief Scientific Officer & Head of Research | 0 | 1955 |
| Gaby Scherer | Senior Vice President & Head of Global Human Resources | 0 | 1961 |
| Benjamin Limal | President of EUCAN Region | 0 | 1973 |
| Julien Gander | Executive Vice President, Chief Legal & Corporate Development Officer and Company Secretary | 0 | 1979 |
| Olivier Lambert | Senior Vice President & Head of Technical Operations | 0 | 1966 |
Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.